Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome.

By Takashi Kadowaki, Toshimasa Yamauchi, N. Kubota, K. Hara, K. Ueki, K. Tobe. Journal of Clinical Investigation, 2006

2,850 citations recorded by the source corpus.

Subfields: Epidemiology, Pharmacology, Physiology

View Paper: https://www.semanticscholar.org/paper/28df6065881aba0cc957941701c29ddc15ff94f1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. B. Spiegelman
2. E. Rosen
3. Jianping Ye
4. S. Kersten
5. C. Day
6. S. Bellentani
7. V. Ratziu
8. H. Cortez‐Pinto

In Pharmacology

1. Manabu T. Nakamura

In Physiology

1. B. Spiegelman
2. E. Rosen
3. Jianping Ye
4. S. Kersten
5. Myung‐Sook Choi
6. H. Fang
7. R. L. Judd
8. U. Jung

Citations in the corpus

• Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. (2007, background): “A decrease in adiponectin (ACRP30) production contributes to pathogenesis of insulin resistance (23).”
• Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. (2013, background): “Adiponectin controls systemic glucose and lipid homeostasis via its endocrine actions on several major metabolic organs, including liver and skeletal muscle (Kadowaki et al., 2006).”
• Impact of Obesity and Metabolic Syndrome on Immunity. (2016, background): “Adiponectin is known to inhibit sterol regulatory element-binding protein-1c-induced lipogenesis and NF-kB-mediated proinflammatory gene transcription, and promotes PPAR-a and -g transcriptional activity to increase b-oxidation and glucose transporter type 4 translocation (90).”
• Cardiac remodeling in obesity. (2008, background): “Antidiabetic (162), anti-inflammatory (348), and antihypertensive (259) effects have all been established to occur in response to adiponectin.”
• Metabolic Syndrome and Insulin Resistance: Underlying Causes and Modification by Exercise Training (2013, neutral): “Interestingly, polymorphisms in both adiponectin receptors are associated with insulin resistance and T2D (135, 324, 429).”
• Nonalcoholic fatty liver disease: pathology and pathogenesis. (2010, background): “Many therapies associated with improvement in NAFLD have also resulted in increased plasma adiponectin levels including weight loss, decreasing visceral adiposity, dietary PUFA, and PPARγ ligands [thiazolidinediones (TZDs)] (112).”
• Regulation of energy metabolism by long-chain fatty acids. (2014, background): “Moreover, this hypothesis explains the requirement of disulfide bond formation for increased insulin sensitivity [204] because only hexamer or larger adiponectin multimers, but not trimers, can form intercellular bridges between two adipocytes.”
• Adiponectin Regulation and Function (2018, positive): “Adiponectin decreases NF-kB activation by Toll-like receptor ligands, leading to a suppression of M1 macrophage proliferation and function (2, 126, 335, 378, 379).”
• Adipocytes as regulators of energy balance and glucose homeostasis (2006, background): “Adiponectin The hormone adiponectin was identified by several different groups and given various names (for example, apM1, GBP28, AdipoQ and ACRP30”
• Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. (2009, background): “Findings from animal studies and metabolic studies in humans suggest several mechanisms through which adiponectin may decrease the risk of type 2 diabetes, including suppression of hepatic gluconeogenesis, stimulation of fatty acid oxidation in the liver, stimulation of fatty acid oxidation and gluc”
• The Inflammasome-Mediated Caspase-1 Activation Controls Adipocyte Differentiation and Insulin Sensitivity (2010, background): “Importantly, secretion of adiponectin, a key regulator of insulin sensitivity (Kadowaki et al., 2006), was significantly elevated in caspase-1-deficient adipocytes (Figure 3C).”
• Obesity and Its Metabolic Complications: The Role of Adipokines and the Relationship between Obesity, Inflammation, Insulin Resistance, Dyslipidemia and Nonalcoholic Fatty Liver Disease (2014, background): “It has been reported that the adiponectin receptors, adiponectin receptor (AdipoR)1 and AdipoR2 are reduced in obesity-related insulin resistance and mediate the anti-metabolic actions of adiponectin [164].”
• Serum FGF21 Levels Are Increased in Obesity and Are Independently Associated With the Metabolic Syndrome in Humans (2008, background): “Adiponectin is a well-characterized adipokine with potent insulin-sensitizing, anti-inflammatory, and anti-atherosclerotic activities (37).”